Thurston Springer Miller Herd & Titak Inc. Acquires 17,000 Shares of Assertio Holdings, Inc. (NASDAQ:ASRT)

Thurston Springer Miller Herd & Titak Inc. lifted its stake in shares of Assertio Holdings, Inc. (NASDAQ:ASRT) by 33.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 67,500 shares of the company’s stock after acquiring an additional 17,000 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in Assertio were worth $59,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ASRT. Palumbo Wealth Management LLC grew its stake in Assertio by 9.3% in the third quarter. Palumbo Wealth Management LLC now owns 185,961 shares of the company’s stock valued at $219,000 after acquiring an additional 15,863 shares during the period. Empowered Funds LLC grew its position in Assertio by 5.4% in the 3rd quarter. Empowered Funds LLC now owns 431,913 shares of the company’s stock valued at $510,000 after purchasing an additional 21,976 shares during the period. Captrust Financial Advisors bought a new stake in Assertio during the 3rd quarter valued at $26,000. Point72 DIFC Ltd acquired a new position in Assertio during the second quarter worth $40,000. Finally, Geode Capital Management LLC lifted its stake in shares of Assertio by 4.1% in the third quarter. Geode Capital Management LLC now owns 1,074,852 shares of the company’s stock valued at $1,269,000 after buying an additional 42,750 shares in the last quarter. 48.96% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Assertio news, Director Heather L. Mason bought 75,000 shares of the stock in a transaction dated Monday, November 18th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $60,000.00. Following the purchase, the director now directly owns 287,650 shares of the company’s stock, valued at approximately $230,120. This trade represents a 35.27 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.20% of the company’s stock.

Assertio Stock Up 2.8 %

ASRT opened at $0.83 on Friday. Assertio Holdings, Inc. has a fifty-two week low of $0.73 and a fifty-two week high of $1.80. The firm has a market capitalization of $78.99 million, a P/E ratio of -1.13, a PEG ratio of 3.35 and a beta of 0.78. The company’s 50-day moving average is $0.90 and its 200 day moving average is $1.13. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.01 and a quick ratio of 1.57.

Assertio (NASDAQ:ASRT) last posted its earnings results on Monday, November 11th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.02. The firm had revenue of $29.20 million for the quarter, compared to analysts’ expectations of $29.29 million. Assertio had a negative net margin of 54.46% and a positive return on equity of 3.79%. During the same quarter last year, the firm earned ($0.01) EPS. Research analysts expect that Assertio Holdings, Inc. will post -0.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ASRT shares. StockNews.com upgraded shares of Assertio from a “hold” rating to a “buy” rating in a report on Wednesday, November 13th. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Assertio in a report on Monday, December 16th.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.